Two Babies Pass Away On The Same Day They Received RSV Monoclonal Antibody Shot, Report Says

From 100PercentFedUp - READ ORIGINAL

Some media, including videos, may only be available to view at the original.  

Share this:

Children’s Health Defense reports that two infants died the same day they received nirsevimab, marketed under the brand name Beyfortus, a monoclonal antibody shot approved for infants to prevent respiratory syncytial virus (RSV).

“According to the VAERS reports, a 27-day-old boy died immediately upon receiving the shot and an infant girl was found not breathing by her father 7 hours after receiving the shot,” Children’s Health Defense stated.

Children’s Health Defense said it obtained Freedom of Information Act (FOIA) documents from the Centers for Disease Control and Prevention (CDC) showing the babies died on the day they received the shots.

“The deaths were reported in VAERS as resulting from mistaken administration of Pfizer’s adult RSV vaccine, but the CDC internal emails obtained by CHD indicate the babies had been administered Beyfortus, the brand name for nirsevimab, manufactured by AstraZeneca and Sanofi,” Dr. Kat Lindley wrote, citing The Defender. 

The Defender reports:

The U.S. Food and Drug Administration (FDA) approved the drug in July 2023 and the CDC recommended it in August 2023 for infants under 8 months or high-risk infants up to 24 months of age.

In clinical trials for the drug, 12 infants died, but an FDA spokesperson told CNBC when the drug was approved that “none of the deaths appeared to be related to nirsevimab.”

After the CDC recommended the drug, it expanded the 2024 childhood vaccine schedule and included nirsevimab for infants whose mothers did not receive the RSV vaccine — also recently approved — during pregnancy.

The CDC’s childhood immunization schedule lists the CDC-recommended shots for children from birth through age 18. Pediatricians and other clinicians typically use the schedule to make recommendations to parents, and schools use it to set vaccine requirements.

Monoclonal antibodies are not technically vaccines. Vaccines stimulate the individual’s immune system to trigger an immune response. Monoclonal antibodies are proteins cloned in a lab that act like antibodies, seeking out antigens in the body to destroy them just like people’s own antibodies do, according to the Cleveland Clinic.

When the CDC expanded the 2024 vaccine schedule, it changed the description of the schedule to be for “vaccines and other immunizing agents,” before adding the RSV monoclonal antibodies to the list.

“Imagine taking your 27 day old baby to the doctor and they talk you into giving him the new RSV ‘vaccine’ by Pfizer called ABRYSVO. You then watch as he dies immediately after taking it right in front of your eyes in the doctors office,” Champagne Joshi wrote, including one of the VAERS reports.


* Image from Champagne Joshi X Post *

Cont. from The Defender:

CDC researchers in May published an article in Pediatrics reporting that at least 34 babies were mistakenly given the RSV vaccine — made by either Pfizer or GSK and authorized for adults — and one of those babies was hospitalized.

Thirty-one of the children under age 2 identified in the study who were mistakenly vaccinated between Aug. 21, 2023, and March 18, 2024, were less than 8 months old. Seven reports described adverse health events including fevers, vomiting, coughing and injection site swelling.

One baby was hospitalized for cardiorespiratory arrest within 24 hours of receiving the GSK RSV vaccine. The baby had a history of congenital heart disease and was hospitalized at the time of the VAERS report.

When the paper was published, The Defender worked with Benavides and identified at least two other babies in the VAERS system reported to have received the RSV vaccine and died within hours of vaccination.

The Defender reached out to the CDC in a series of emails inquiring about why the babies were not included in the study, but the CDC declined to provide details about its knowledge of the reports.

Notify of

Inline Feedbacks
View all comments